Home › Cholesterol › NCT07477704
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Weekly Alirocumab in Adults With Hypercholesterolemia
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Key Inclusion Criteria: 1\. Participant has elevated LDL-C level, as defined in the protocol Key Exclusion Criteria: 1. Participant plans to initiate or change dose of lipid-lowering therapy 2. Use of any PCSK9 inhibitors NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply
About the study
This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).
The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times
What is being tested
- Alirocumab (drug)
Sponsor: Regeneron Pharmaceuticals · Participants: 420 · Started: Jun 17, 2026
Contact the study team
- Clinical Trials Administrator · Phone: 844-734-6643
Official record on ClinicalTrials.gov — NCT07477704
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.